SNN Stock Recent News

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own platelets and plasma that, once applied, may assist the natural healing process by maintaining a moist wound environment.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Investors with an interest in Medical - Products stocks have likely encountered both Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

Investors with an interest in Medical - Products stocks have likely encountered both Smith & Nephew (SNN) and Stryker (SYK). But which of these two stocks is more attractive to value investors?

Citi has reiterated its buy rating on Smith & Nephew PLC (LSE:SN) following recent meetings with the company's CEO and CFO. The bank highlights a constructive tone around the business despite the decision not to upgrade full-year guidance, citing global uncertainties and tough fourth-quarter comparisons.

Smith & Nephew's interim results confirm solid progress, with revenue up 5% and strong cash flow growth, supporting my continued 'buy' rating. Dividend growth has resumed after years of stagnation, and a $500m buyback signals management's confidence in cash generation, though yield remains modest. The company's recovery is gaining traction, even if ambitious margin targets remain unmet; momentum is building across all business units and regions.

Citi has stuck with its ‘buy' call on Smith & Nephew PLC (LSE:SN) after the company delivered quarterly results that were, in Citi's words, “meaningfully better than expected”, and announced a $500mn share buyback that caught many by surprise. In its latest note, it highlighted that Smith & Nephew's organic growth for the second quarter came in “200–250 basis points above Visible Alpha consensus" and its own forecasts, driven by strong performances across the board.

Smith & Nephew plc (NYSE:SNN ) Q2 2025 Earnings Conference Call August 5, 2025 3:30 AM ET Company Participants Deepak S. Nath - CEO & Director John Terence Rogers - CFO & Executive Director Conference Call Participants David James Adlington - JPMorgan Chase & Co, Research Division Dylan van Haaften - Stifel, Nicolaus & Company, Incorporated, Research Division Graham Doyle - UBS Investment Bank, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division Jack Reynolds-Clark - RBC Capital Markets, Research Division Kane Slutzkin - Deutsche Bank AG, Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Robert John Davies - Morgan Stanley, Research Division Samuel England - Joh.

Smith & Nephew PLC (LSE:SN) shares surged 14% after the company reported robust revenue and profit growth, and announced a $500 million share buyback to be launched in the second half of the year. The medical technology group's second-quarter revenue climbed 7.8% year-on-year to $1.55 billion, with all business units and regions outperforming the first quarter.

As of Aug. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.